Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

NCT06108050 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT06108050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06108050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
November 7, 2023
Completion date
May 31, 2028
Enrollment
177 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, metastatic solid tumor